Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.740 +0.150 (+5.79%)

Streaming Delayed Price Updated: 9:47 AM EDT, Mar 25, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	37,690
Open	2.660
Bid (Size)	2.720 (200)
Ask (Size)	2.740 (400)
Prev. Close	2.590
Today's Range	2.655 - 2.740
52wk Range	0.8551 - 3.600
Shares Outstanding	40,501,258
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

March 19, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

March 17, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	+35.6%	+35.6%
1 Month	+6.2%	+6.2%
3 Month	+26.3%	+26.3%
6 Month	+122.8%	+122.8%
1 Year	+121.0%	+121.0%

More News

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

March 16, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Acumen Pharmaceuticals's Earnings: A Preview ↗

August 11, 2025

Via Benzinga

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

March 10, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

March 03, 2026

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

These stocks have an unusual volume in today's session ↗

January 28, 2026

Via Chartmill

Tuesday's after hours session: top gainers and losers ↗

January 27, 2026

Via Chartmill

The market is filled with gapping stocks in Monday's session. ↗

January 26, 2026

Via Chartmill

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

December 02, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

November 18, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

November 17, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates ↗

November 12, 2025

Via Chartmill

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

November 12, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Preview: Acumen Pharmaceuticals's Earnings ↗

November 11, 2025

Via Benzinga

Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors

November 10, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

November 05, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

November 04, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 25, 2025

Via Benzinga

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

August 26, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

August 12, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

August 05, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025

July 28, 2025

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

Frequently Asked Questions

Is Acumen Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Acumen Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Acumen Pharmaceuticals, Inc. - Common Stock trade on?

Acumen Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Acumen Pharmaceuticals, Inc. - Common Stock is ABOS on the Nasdaq Stock Market

What is the current price of Acumen Pharmaceuticals, Inc. - Common Stock?

The current price of Acumen Pharmaceuticals, Inc. - Common Stock is 2.740

When was Acumen Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Acumen Pharmaceuticals, Inc. - Common Stock was at 03/25/26 09:47 AM ET

What is the market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Acumen Pharmaceuticals, Inc. - Common Stock is 110.97M

How many shares of Acumen Pharmaceuticals, Inc. - Common Stock are outstanding?

Acumen Pharmaceuticals, Inc. - Common Stock has 111M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.